|
|
|
Volumn 87, Issue 3, 2004, Pages 34-36
|
|
New biologic therapies for psoriatic disease.
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ALEFACEPT;
BIOLOGICAL RESPONSE MODIFIER;
EFALIZUMAB;
HYBRID PROTEIN;
IMMUNOGLOBULIN G;
IMMUNOSUPPRESSIVE AGENT;
INFLIXIMAB;
MONOCLONAL ANTIBODY;
TNFR FC FUSION PROTEIN;
TNFR-FC FUSION PROTEIN;
TUMOR NECROSIS FACTOR ALPHA;
TUMOR NECROSIS FACTOR RECEPTOR;
ARTICLE;
CLINICAL TRIAL;
DRUG ANTAGONISM;
DRUG EFFECT;
HUMAN;
IMMUNOLOGY;
PHYSIOLOGY;
PSORIASIS;
T LYMPHOCYTE;
TREATMENT OUTCOME;
ANTIBODIES, MONOCLONAL;
BIOLOGICAL RESPONSE MODIFIERS;
CLINICAL TRIALS;
HUMANS;
IMMUNOGLOBULIN G;
IMMUNOSUPPRESSIVE AGENTS;
PSORIASIS;
RECEPTORS, TUMOR NECROSIS FACTOR;
RECOMBINANT FUSION PROTEINS;
T-LYMPHOCYTES;
TREATMENT OUTCOME;
TUMOR NECROSIS FACTOR-ALPHA;
|
|
EID: 3042581430
PISSN: 0026556X
EISSN: None
Source Type: Journal
DOI: None Document Type: Article |
|
Times cited : (5)
|
|
References (0)
|
